Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III

M. J. Reike; M. A. Ingersoll; D. C. Müller; T. C.M. Zuiverloon; T. Strandgaard; A. M. Kamat; S. B. Williams; R. Seiler; T. Todenhöfer; L. Dyrskjøt; R. Nawroth; P. Goebell; B. Schmitz-Dräger; J. P. Sfakianos; J. Meeks; A. Horowitz; P. C. Black

doi:10.1016/j.urolonc.2022.09.012

Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III

M. J. Reike, M. A. Ingersoll, D. C. Müller, T. C.M. Zuiverloon, T. Strandgaard, A. M. Kamat, S. B. Williams, R. Seiler, T. Todenhöfer, L. Dyrskjøt, R. Nawroth, P. Goebell, B. Schmitz-Dräger, J. P. Sfakianos, J. Meeks, A. Horowitz, P. C. Black^*

^*Corresponding author for this work

Urology

Research output: Contribution to journal › Review article › Academic › peer-review

Abstract

Bacillus Calmette-Guerin (BCG) remains the only FDA-approved first-line therapy in patients with high-risk non-muscle invasive bladder cancer. Recurrences, even after adequate BCG therapy, are common and the efficacy of second-line therapies remains modest. Therefore, early identification of patients likely to recur and treatment after recurrence remain critical unmet needs in the clinical care of bladder cancer patients. To address these deficits, a better understanding of the mechanisms of resistance to BCG-therapy is needed. The virtual update of the International Bladder Cancer Network (IBCN) on the biology of response to BCG focused on potential mechanisms and markers of resistance to intravesical BCG therapy. The insights from this meeting will be highlighted and put into context of previously reported mechanisms of resistance to BCG in this review.

Original language	English
Journal	Urologic Oncology: Seminars and Original Investigations
DOIs	https://doi.org/10.1016/j.urolonc.2022.09.012
Publication status	E-pub ahead of print - 18 Oct 2022

Bibliographical note

Funding Information:
Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), RE 4782/1-1.

Publisher Copyright:
© 2022 Elsevier Inc.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.urolonc.2022.09.012

Cite this

Reike, M. J., Ingersoll, M. A., Müller, D. C., Zuiverloon, T. C. M., Strandgaard, T., Kamat, A. M., Williams, S. B., Seiler, R., Todenhöfer, T., Dyrskjøt, L., Nawroth, R., Goebell, P., Schmitz-Dräger, B., Sfakianos, J. P., Meeks, J., Horowitz, A., & Black, P. C. (2022). Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III. Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/j.urolonc.2022.09.012

@article{a8c97fa47f60413786575b8d8c5a7ccb,

title = "Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III",

abstract = "Bacillus Calmette-Guerin (BCG) remains the only FDA-approved first-line therapy in patients with high-risk non-muscle invasive bladder cancer. Recurrences, even after adequate BCG therapy, are common and the efficacy of second-line therapies remains modest. Therefore, early identification of patients likely to recur and treatment after recurrence remain critical unmet needs in the clinical care of bladder cancer patients. To address these deficits, a better understanding of the mechanisms of resistance to BCG-therapy is needed. The virtual update of the International Bladder Cancer Network (IBCN) on the biology of response to BCG focused on potential mechanisms and markers of resistance to intravesical BCG therapy. The insights from this meeting will be highlighted and put into context of previously reported mechanisms of resistance to BCG in this review.",

author = "Reike, {M. J.} and Ingersoll, {M. A.} and M{\"u}ller, {D. C.} and Zuiverloon, {T. C.M.} and T. Strandgaard and Kamat, {A. M.} and Williams, {S. B.} and R. Seiler and T. Todenh{\"o}fer and L. Dyrskj{\o}t and R. Nawroth and P. Goebell and B. Schmitz-Dr{\"a}ger and Sfakianos, {J. P.} and J. Meeks and A. Horowitz and Black, {P. C.}",

note = "Funding Information: Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), RE 4782/1-1. Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2022",

month = oct,

day = "18",

doi = "10.1016/j.urolonc.2022.09.012",

language = "English",

journal = "Urologic Oncology: Seminars and Original Investigations",

issn = "1078-1439",

publisher = "Elsevier Inc.",

}

Reike, MJ, Ingersoll, MA, Müller, DC, Zuiverloon, TCM, Strandgaard, T, Kamat, AM, Williams, SB, Seiler, R, Todenhöfer, T, Dyrskjøt, L, Nawroth, R, Goebell, P, Schmitz-Dräger, B, Sfakianos, JP, Meeks, J, Horowitz, A & Black, PC 2022, 'Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III', Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/j.urolonc.2022.09.012

TY - JOUR

T1 - Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III

AU - Reike, M. J.

AU - Ingersoll, M. A.

AU - Müller, D. C.

AU - Zuiverloon, T. C.M.

AU - Strandgaard, T.

AU - Kamat, A. M.

AU - Williams, S. B.

AU - Seiler, R.

AU - Todenhöfer, T.

AU - Dyrskjøt, L.

AU - Nawroth, R.

AU - Goebell, P.

AU - Schmitz-Dräger, B.

AU - Sfakianos, J. P.

AU - Meeks, J.

AU - Horowitz, A.

AU - Black, P. C.

PY - 2022/10/18

Y1 - 2022/10/18

N2 - Bacillus Calmette-Guerin (BCG) remains the only FDA-approved first-line therapy in patients with high-risk non-muscle invasive bladder cancer. Recurrences, even after adequate BCG therapy, are common and the efficacy of second-line therapies remains modest. Therefore, early identification of patients likely to recur and treatment after recurrence remain critical unmet needs in the clinical care of bladder cancer patients. To address these deficits, a better understanding of the mechanisms of resistance to BCG-therapy is needed. The virtual update of the International Bladder Cancer Network (IBCN) on the biology of response to BCG focused on potential mechanisms and markers of resistance to intravesical BCG therapy. The insights from this meeting will be highlighted and put into context of previously reported mechanisms of resistance to BCG in this review.

AB - Bacillus Calmette-Guerin (BCG) remains the only FDA-approved first-line therapy in patients with high-risk non-muscle invasive bladder cancer. Recurrences, even after adequate BCG therapy, are common and the efficacy of second-line therapies remains modest. Therefore, early identification of patients likely to recur and treatment after recurrence remain critical unmet needs in the clinical care of bladder cancer patients. To address these deficits, a better understanding of the mechanisms of resistance to BCG-therapy is needed. The virtual update of the International Bladder Cancer Network (IBCN) on the biology of response to BCG focused on potential mechanisms and markers of resistance to intravesical BCG therapy. The insights from this meeting will be highlighted and put into context of previously reported mechanisms of resistance to BCG in this review.

UR - http://www.scopus.com/inward/record.url?scp=85140764438&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2022.09.012

DO - 10.1016/j.urolonc.2022.09.012

M3 - Review article

C2 - 36266219

AN - SCOPUS:85140764438

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

ER -

Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this